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Abstract: Antibody-functionalized silicon nanowire field-effect transistors have been shown to exhibit excellent 
analyte detection sensitivity enabling sensing of analyte concentrations at levels not readily accessible by other 
methods. One example where accurate measurement of small concentrations is necessary is detection of serum 
biomarkers, such as the recently discovered tumor necrosis factor receptor superfamily member TROY 
(TNFRSF19), which may serve as a biomarker for melanoma. TROY is normally only present in brain but it is 
aberrantly expressed in primary and metastatic melanoma cells and shed into the surrounding environment. In 
this study, we show the detection of different concentrations of TROY in buffer solution using top-down 
fabricated silicon nanowires. We demonstrate the selectivity of our sensors by comparing the signal with that 
obtained from bovine serum albumin in buffer solution. Both the signal size and the reaction kinetics serve to 
distinguish the two signals. Using a fast-mixing two-compartment reaction model, we are able to extract the 
association and dissociation rate constants for the reaction of TROY with the antibody immobilized on the 
sensor surface.   
I. Introduction 
While the incidence of many common cancers is decreasing, according to the American Cancer Society the 
incidence of melanoma has been rising by about 3% per year. Statistical analysis shows there will be an 
estimated 76,690 new cases in 2013, with 9,480 deaths. If melanoma is detected early, the five-year survival rate 
is 98% but this rate rapidly decreases to 62% for regional disease and to 15% and lower when tumors have 
spread to distant sites. While treatment options for advanced stage melanoma had stagnated for decades, 
recently a number of new targeted therapies have become available, but, unfortunately, even these drugs are 
only expected to increase survival by several months in certain patient groups before they too inevitably 
relapse.1,2 If an early diagnosis can be made before metastatic disease becomes clinically detectable and virtually 
incurable, it may be possible to effectively treat patients because the tumor burden is still very low. But 
presently no such early detection method exists. Recently, it was found that a member of the tumor necrosis 
factor receptor superfamily, called TROY (or TNFRSF19), may serve as a melanoma-specific biomarker.3 
TROY is widely expressed during embryogenesis, but in human adults it is primarily restricted to the brain. 
Studies have shown that TROY is expressed in all investigated primary and metastatic melanoma cells and 
tissue samples, but not in melanocytes found in normal skin biopsies and primary skin cell cultures. Neither is it 
detectable in other (skin) tumor cells.3 Many membrane receptors are shed into the surrounding environment4,5 
and our preliminary studies showed that the extracellular domain (ECD) of TROY is also shed (data not shown). 
This suggests that TROY may serve as a novel surrogate serum biomarker for circulating and metastatic 
melanoma cells and a Point-Of-Care (POC) diagnostic blood test that can detect abnormally elevated levels of 
TROY ECD may help revolutionize early diagnosis and treatment for this disease. This project intends to 
address this huge unmet clinical need by first generating and characterizing a nanosensor dedicated to detection 
of low quantities of TROY in vitro as a first step towards developing this sensor technology towards clinical use 
as a novel POC device to detect occult metastatic disease. 
With recent advances in nanotechnology many novel biosensing systems have been developed.6 Among those 
different techniques for biomarker sensing especially electrical detection using ion-sensitive Field-Effect 
Transistors (FET) holds a great promise to revolutionize biosensing7 due to its direct, label-free8 sensing and 
highly scalable nature.9 Silicon nanowire FETs have been used to detect pH,10,11,12,13 various cancer 
biomarkers,14,15,16,17 biomarkers indicative of acute myocardial infarction,18,19,20,21 glucose22 and viruses.23,24 
Sensitivity of detection of molecules is enhanced by their high surface-to-volume ratio, permitting nanowires to 
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sense surface binding events hard to achieve by bulk detection schemes. Specificity is generally achieved by 
immobilization of antibodies to the nanowire surface by silanization of the sample and subsequent covalent 
binding of the antibody through amide bonds. The binding of antigens to the paratope of the immobilized 
antibodies changes the charge distribution in the biofunctionalized layer. This can either happen because the 
antigen is charged in solution or because of the adsorption process. The result is a change of the electric field 
through the nanowire, which leads to accumulation or depletion of charge carriers, hence modulating its 
conductance.25  For obvious reasons, this is also termed molecular gating.26 The direct sensing of molecules of 
interest eliminates the need for labeling and long incubation times reducing the cost and time needed for 
detection. The data is essentially recorded in real time, which allows the evaluation of reaction kinetics. This 
should also enable distinguishing between specific and nonspecific binding due to their different reaction 
kinetics. The nanowires’ ultra-low power consumption makes them ideal candidates for implantable biosensors 
to control biological function in vivo. There are several challenges associated with the use of semiconducting 
nanowires for the use of biosensors.27 The major problem is electrostatic screening of charges in the 
biofunctionalized layer in physiological solutions due to their high electrolyte concentration. An indication of 
the screening range is the Debye length. It is the characteristic decay length of the potential in the Debye-Hückel 
approximation.28 For physiological solutions it is less than 1 nm. Several groups have made efforts to increase 
this Debye length. Stern et al. used a microfluidic purification chip to pre-clean blood and transfer the antigens 
of interest to a purified buffer with low salt concentration.29  Another approach is the use of high frequency to 
disrupt the electrical double layer.30 A more simple solution is the use of antibody fragments to allow for 
binding of the biomarker of interest in the vicinity of the nanowire.19  
In this study, we have detected the novel melanoma biomarker TROY using silicon nanowire FETs 
functionalized with the antibody fragments that are antigen binding (FAB). These fragments are only a fraction 
of the size of the immunoglobulin, yet retain the ability to bind antigens with high binding strength. Therefore, 
the antigens bind in closer vicinity to the sensing element, the nanowire. The detection limit in pure low-salt 
buffer was less than 10 ng/ml. By real-time data recording we extracted the reaction kinetics for binding of 
TROY to its corresponding antibody. Nonspecific binding tests with bovine serum albumin (BSA) showed 
adsorption at longer time scales, allowing for further discrimination against any non-specific background 
signals.  
II. Experimental Approach 
We have fabricated silicon nanowires in a top-down approach starting with SOI wafer (100 nm top silicon layer, 
10 Ωcm, B-doped, from Soitec) which is diced and cleaned with acetone, isopropyl alcohol and a 2:3 mixture of 
hydrogen peroxide and sulfuric acid (piranha, all from J.T. Baker). First, gold electrodes are formed by 
photolithography (Karl Suss, MA 6) and electron beam evaporation. A small layer of titanium (10 nm) is used 
for adhesion of the gold layer (50 nm) and a chromium layer is evaporated last as mask for subsequent etching 
(all from Kurt J. Lesker). Then, the nanowires (usually a set of 20 single wires about 300 nm in width and 100 
nm in height) are defined by electron beam lithography (JEOL JSM 6400) and a chromium layer is evaporated 
as mask for isotropic dry etching in a reactive ion etcher (Plasma-Therm 790) using tetrafluoromethane and 
oxygen. Afterwards, the chromium layer is etched off chemically (chromium etchant 1020 from Transene), 
which leaves silicon nanowires on silicon oxide electrically connected by gold electrodes. In order to use the 
device in solution, the electrodes and wires need to be electrically insulated. This is achieved by growing 100 
nm of aluminum oxide on the electrodes and 20 nm of aluminum oxide on the wires using atomic layer 
deposition (CambridgeNanoTech, Savannah 100). Additionally, a micrometer thick layer of poly(methyl 
methacrylate) (PMMA, from MicroChem) is overexposed on top of the electrodes by e-beam lithography. A 
finished set of wires is shown in Figure 1a. The nanowires gain selectivity by immobilized antibodies on the 
nanowire surface. For that purpose the surface is hydroxylated with an oxygen plasma in a plasma asher (PVA 
TePla, M4L, 300 mW power, 300 sccm flow rate for 2 minutes) and silanized by immersion in ethanol 
containing 5% (3-aminopropyl)triethoxysilane (APTES, both from Sigma-Aldrich) and 5% water for 20 minutes 
followed by 30 min annealing at 110 °C. The antibody FABs (provided by Biosite Diagnostics) were generated 
by proprietary phage-display against the TROY ECD. They are N-hydroxysuccinimide (NHS)-activated by 
adding them to an MES (from Sigma-Aldrich) buffer containing NHS (from Pierce) and 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide (EDC, from Sigma-Aldrich). They are then reacted with the amine groups 
on the surface of the nanowires for 2 hours (Figure 1b). Different concentrations of TROY are detected by 
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sealing the functionalized device in a fluid chamber31 together with an Ag/AgCl reference electrode (A-M 
Systems) and flowing buffer solutions with TROY over the wires (Figure 1c). The conductance through the 
nanowire changes upon binding of the antigen due to a change in the charge distribution. This is measured by 
adding a small, low-frequency AC voltage to a DC voltage using a noninverting summing circuit31 and 
measuring the response using a lock-in-amplifier (EG&G 7260) referenced to the same frequency as the AC 
voltage. The signal is essentially the slope of the source-drain current-voltage curve, or differential conductance.   
 
 
Figure 1. (a) Electron micrograph of two separate sets of silicon nanowires with the electrical connections 
insulated from solution by a micrometer thick layer of poly(methyl methacrylate) (PMMA). (b) Immobilization 
of the antibody FAB to the silanized nanowire using NHS/EDC coupling chemistry. The FAB has one constant 
and one variable domain from each heavy and light chain of the antibody (constant heavy (CH), constant light 
(CL), variable heavy (VH) and variable light (VL). It binds with its C-terminal end to the nanowire exposing the 
paratope at its variable end to the solution. (c) The sensing nanowires are sealed in a fluid chamber with an inlet 
and outlet at opposing ends. Their conductance is tunable by a reference electrode immersed in the solution and 
a back gate connected to the bulk silicon.  
III. Results and Discussion 
A. Detection of TROY 
The recently-found potential biomarker for melanoma TROY opens new opportunities for early and confident 
diagnosis of melanoma as well as for monitoring recurrence and spreading of the cancer and responsiveness to 
therapy in established patients that are undergoing treatment.  In order to make full use of the biomarker a 
reliable, fast and cheap biosensor needs to be developed for its detection and validation. We have used silicon 
nanowire FETs functionalized with the antibody FABs to detect TROY in pure 2 mM PBS buffer. For that 
purpose buffer solutions were prepared containing different concentrations of the antigen but equal salt 
concentrations and pH values to ensure that the signal is due to binding of the antigen. Devices were 
prescreened with respect to their I-V characteristics and an optimal working point was determined.15 Throughout 
one measurement the differential conductance through the sensor was recorded in real-time. After establishing a 
conductance baseline with pure buffer, solutions containing the antigen and a washing buffer were then injected 
 
4 
successively into the fluid chamber sealing the device. A syringe pump was used to allow for continuous flow. 
For analysis of the data the change in conductance after injection of buffer containing the antigen was calculated 
after saturation with respect to the baseline.  
The change in conductance for three different measurements with respect to TROY concentration is shown in 
Figure 2. The relationship is linear on a log-log plot, which means that the intersection is zero, hence there is no 
significant systematic error. The error is determined by the standard deviation of each signal after saturation. 
This also sets a limit for detection and is illustrated in Figure 2 by the patterned area. Where the line crosses into 
this region determines the detection limit of the device. It corresponds to less than 10 ng/ml or 200 pM. In order 
to test specificity pure buffer solutions with different concentrations of BSA were flown over the device. For the 
same concentrations that were measured with TROY the signal for the BSA samples was below the detection 
limit of a conductance change of 0.11 nS. However, for a BSA concentration of 0.1 mg/ml the signal size was 
similar to the one generated by a TROY concentration of 50 ng/ml. As will be shown later though, the signals 
differ significantly due to their different adsorption times. 
The signal for TROY is in the linear regime of a Langmuir adsorption isotherm, which makes extraction of 
the equilibrium constant highly inaccurate. Assuming a linear increase of conductance with charge distribution 
change in the biofunctionalized layer the change in conductance is proportional to the concentration of bound 
antigen-antibody complex, which can be modeled by a Langmuir adsorption isotherm. Therefore, the change in 
conductance ΔG is proportional to 
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where CTROY is the antigen concentration in the buffer and Keq is the equilibrium constant. Approximation of the 
curve in Figure 2 yields an equilibrium constant of 12 ± 4 nM.  
 
Figure 2. Sensing of the melanoma biomarker TROY using FAB-functionalized nanowires. The conductance 
change of the nanowires in response to different concentrations of TROY in 2 mM PBS buffer (squares, circles 
and triangles) is compared to the response to BSA (stars) in the same buffer. A linear dependence between 
conductance change and concentration is observed in the 10 ng/ml to 1 µg/ml regime of TROY concentration 
(the dashed line is a guide to the eye). The error bars are the standard deviation of the signal (they are expanded 
for lower concentrations due to the nature of the logarithmic plot). The largest standard deviation is 0.2 nS, 
which is illustrated by the shaded area. Hence, where the line crosses into the shaded area determines the 
detection limit. It corresponds to a concentration below 10 ng/ml.   
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B. Reaction kinetics analysis 
The collection of real-time data using the silicon nanowire FETs allows evaluation of the binding curves of 
TROY to the antibody FAB. By comparing the binding curves with reaction kinetics models of the antigen-
antibody complex association and dissociation rate constants can be extracted as successfully demonstrated by 
Duan et al.32 We start with a two-compartment reaction model33 
 ( ) ( )( )boundboundSSTROYmS ckccCkSCCVkdt
dCV 1max1 −+−−−=
 
   (2a)
 
( ) boundboundSbound ckccCkdt
dc
1max1 −−−=
 
      (2b)
 where V is the compartment volume, S is the surface area, CS is the antigen concentration in the surface 
compartment, cmax is the concentration of antibody FABs on the surface and cbound is the concentration of bound 
antigen-antibody complex; km, k1 and k-1 are the transport rate constant, the association and the dissociation rate 
constant, respectively. We have to pay attention to the fact that kinetics are both evaluated in the volume and on 
the surface, hence CS and CTROY have dimensions of a volume concentration and cmax and cbound have dimensions 
of a surface concentration. No analytical solutions are known to these equations, but, under certain assumptions, 
we can simplify them and fit the binding data to the model. In our case a fast-mixing model for adsorption can 
be applied which is not diffusion-limited. In the following we will justify this choice.  
A measure for the ratio of convective transport rate to diffusive transport rate is the dimensionless Peclét 
number. There are two Peclét numbers associated with our experiment,34 one for our fluid chamber design (Pec) 
and one that takes the nanowire dimensions into account (Pen). They depend on the volumetric flow rate Q, the 
chamber width wc and height h, the diffusion constant of the antigen D and the nanowire width wn. The two 
Peclét numbers are then calculated34 
Dw
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= .          (3b) 
The parameters of our setup are Q = 30 µl/min, wc = 1 mm, h = 0.1 mm, wn = 20 × 300 nm, since we have a set 
of 20 wires.  Assuming a diffusion constant of 10 µm2/s we obtain a Peclét number for the chamber Pec = 
50,000 >> 1. This indicates that antigen transport in the chamber is dominated by convection. The second Peclét 
number Pen = 900 is still much larger than 1 and hence convection is also the dominant transport mechanism to 
the sensor and supply of antigen to the nanowire is not limited by diffusion. This means that the concentration in 
the surface compartment is essentially the same as the volume concentration and equation (2) simplifies to: 
( ) boundboundTROYbound ckccCkdt
dc
1max1 −−−= .       (4)
 This can be solved analytically and then the conductance change ΔG is proportional to 
( )tkCk TROYeG 111 −+−−∝Δ .         (5) 
For desorption the conductance change is proportional to 
tkeG 1−−∝Δ            (6) 
Equation (5) was used to approximate the real-time antigen-antibody binding data (Figure 3a). The curves were 
time-shifted to ensure that injection of the buffer containing TROY happens at time zero. The decay constants 
τadsorption and τdesorption were then plotted for the different concentrations to extract the association and dissociation 
constants (Figures 3b and 3c). Due to the small value of k-1 its calculation from the binding curve is not very 
accurate. It is thus calculated from the unbinding curve using equation (6). The association rate constant is (1 ± 
0.2) × 105 mls-1g-1) or (5 ± 1) × 106 s-1M-1.  The dissociation rate constant is 0.13 ± 0.01 s-1. From those two 
values, the equilibrium constant can be calculated according to Keq = k-1 × k1-1 = 26 nM ± 7 nM.  
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Figure 3. (a) Comparison of the nanowire response curves to different concentrations of TROY. The graphs 
were aligned to show injection of buffer containing TROY at the same time (0 s) and starting with the same 
baseline. The errors are estimated from the signal drift to 0.3 nS. For visual clarity they are not shown in the 
graph. The data is approximated by a linear fit for the baseline and by a fast mixing reaction kinetics model 
(equations (5) and (6)) for binding and unbinding. (b) The inverse time constants of the exponential 
approximations to the adsorption data in (a) for different concentrations. The association and dissociation rate 
constants can be extracted from the linear fit according to 1/τadsorption = k1CTROY + k-1. The inset shows the time 
constants τadsorption for different concentrations. (c) The time constants for the desorption data in (a). Error bars in 
(b) and (c) are statistical errors from the fit. 
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For comparison with the reaction kinetics of TROY binding to the antibody FAB, the binding curves for BSA 
are shown in Figure 4a and approximated by exponential decays. Because the binding is nonspecific the time 
constants are much bigger compared to binding of TROY especially for concentrations greater than 1 µg/ml. 
This is emphasized in Figure 4b. To enable direct comparison, the conductance signals were normalized by 
subtraction of the saturation conductance Gsat and subsequent division by the total conductance change ΔGtotal. 
This normalized signal Gnorm was plotted logarithmically to visualize the different time constants.  The 
difference of the binding kinetics for high concentrations of BSA and TROY enables a distinction between 
specific and non-specific binding. 
 
Figure 4. Comparison of the adsorption of TROY and BSA. (a) The nanowire conductance change for different 
concentrations of BSA. The graphs were aligned to show injection of buffer containing BSA at the same time (0 
s) and starting with the same baseline. The data is binned (3 adjacent original data points are averaged and 
summarized into 1). The lines are exponential fits. (b) The data is normalized by the difference between baseline 
and saturation value for the conductance and displayed logarithmically for easy comparison of the time 
constants. The errors are estimated from the uncertainty in the saturation and baseline conductance. The lines are 
guides to the eye. It is obvious that the time constants are different which enables a distinction between specific 
and nonspecific binding. 
IV. Conclusion 
In conclusion, we have shown the detection of TROY in buffer solution using antibody-functionalized silicon 
nanowires. TROY is expressed in primary and metastatic melanoma cells and shed into the surrounding 
environment. It may thus serve as a biomarker for melanoma. The detection limit was about 200 pM. We have 
demonstrated specificity using BSA as control. For similar concentrations as TROY, up to 1 µg/ml, the signal 
due to BSA was below the detection limit. For larger concentrations of BSA, a distinction to TROY is possible 
by comparing the reaction kinetics. The adsorption of TROY, which could be modeled by a fast-mixing two-
compartment reaction model, exhibits much smaller time constants than an exponential fit for the BSA 
adsorption. The association and dissociation rate constants for TROY-antibody binding on the nanowire surface 
were calculated to (5 ± 1) × 106 s-1M-1 and 0.13 ± 0.01 s-1, respectively. For sensing in solutions containing high 
concentrations of salt antibody fragments were used. In further studies this hypothesis should be confirmed and 
eventually TROY should be detected in serum and validated as a melanoma biomarker to advance the technique 
towards a POC device that would be expected to revolutionize melanoma patient care. 
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